首页|艾司西酞普兰对合并焦虑抑郁的冠心病患者神经递质、脑源性神经营养因子的影响

艾司西酞普兰对合并焦虑抑郁的冠心病患者神经递质、脑源性神经营养因子的影响

扫码查看
目的 分析艾司西酞普兰对冠心病合并焦虑抑郁患者神经递质、脑源性神经营养因子(Brain derived neurotrophic factor,BDNF)的影响.方法 选取 2020 年 5 月~2022 年 5 月于我院进行治疗的80例冠心病合并焦虑抑郁患者为研究对象,按照随机数字表法分为观察组(n=40)、对照组(n=40).对照组给予常规对症治疗,观察组在对照组治疗基础上加用艾司西酞普兰.初始剂量为5mg/d,服用3d后依据患者实际情况可增加剂量至10~20mg/d.比较两组治疗效果、治疗前后汉密尔顿焦虑量表(Hamilton anxiety scale,HAMA)、汉密尔顿抑郁量表(Hamilton depression scale,HAMD)评分、神经递质水平、BDNF、血清脂蛋白(lipoprotein,LP)及不良反应发生率.结果 观察组总有效率显著高于对照组(P<0.05);治疗后两组HAMD、HAMA评分均下降,观察组低于对照组(P<0.05);治疗后两组神经递质水平均升高,观察组高于对照组(P<0.05);治疗后两组BDNF、LP水平均升高,观察组高于对照组(P<0.05);两组不良反应发生率比较无明显差异(P>0.05).结论 艾司西酞普兰可显著提高冠心病合并焦虑抑郁患者的治疗效果,改善抑郁、焦虑等负性情绪,调节神经递质、BDNF、LP水平,安全性较高.
Effect of Escitalopram on neurotransmitter and brain-derived neurotrophic factor in patients with coro-nary heart disease complicated with anxiety and depression
Objective To analysis the effect of Escitalopram on neurotransmitter and brain-derived neurotrophic factor in patients with coronary heart disease complicated with anxiety and depression.Method Selection in May 2020 to May 2022 in our hospital for treatment of 80 patients with coronary heart disease(CHD)with anxiety depression as the research object,according to random number table method divided into observation group and control group,40 cases in each.The control group was given conventional symptomatic treatment,and the observation group was given escitalopram with an initial dose of 5 mg/d on the basis of the treatment of the control group,and the dose could be in-creased to 10-20 mg/d after 3 days according to the actual situation of patients.Compare two groups before and after the treatment effect,Hamilton anxiety scale(HAMA)and Hamilton depression scale(HAMD)scores,neurotransmitter levels,BDNF and serum lipoprotein(LP)and the incidence of adverse reactions.Results Observation group total ef-fective rate is significantly higher than control group(P<0.05).Two groups of HAMD,HAMA score decreased after treatment,observation group is lower than the control group(P<0.05).In the two groups after treatment of neurotrans-mitter levels are rising,the observation group than the control group(P<0.05).In the two groups after treatment of BDNF,higher level of LP,observation group is higher than the control group(P<0.05).Incidence of adverse reac-tions to the two groups was no significant difference(P>0.05).Conclusion Escitalopram can significantly improve the treatment effect of coronary heart disease patients with anxiety and depression,regulate negative emotions such as depression and anxiety,improve the levels of neur,which is recommended forclinical application.

EscitalopramCoronary heart diseaseAnxiety and depressionNeurotransmitterBrain-derived neurotrophic factor

杨桂旧、陈红蕾、邹立娇、钟艳珠、陈跃武

展开 >

海南省海南医学院第二附属医院心血管内科一区(海口,570311)

艾司西酞普兰 冠心病 焦虑抑郁 神经递质 脑源性神经营养因子

海南省重点研发计划

SQ2022SHFZ0194

2024

国际精神病学杂志
中南大学

国际精神病学杂志

CSTPCD
影响因子:1.426
ISSN:1673-2952
年,卷(期):2024.51(2)
  • 16